We are live on ! Find out more
NGNE icon

Neurogene
NGNE

39 hedge funds and large institutions have $10.5M invested in Neurogene in 2023 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 15 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

22% more capital invested

Capital invested by funds: $8.66M → $10.5M (+$1.88M)

0.24% less ownership

Funds ownership: 2% → 1.76% (-0.24%)

11% less funds holding

Funds holding: 44 → 39 (-5)

50% less first-time investments, than exits

New positions opened: 5 | Existing positions closed: 10

73% less repeat investments, than reductions

Existing positions increased: 4 | Existing positions reduced: 15

Holders
39
Holders Change
-5
Holders Change %
-11.36%
% of All Funds
0.62%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
5
Increased
4
Reduced
15
Closed
10
Calls
$10K
Puts
–
Net Calls
+$10K
Net Calls Change
+$10K

Top Buyers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
+$152K
2
LCM
Lynx1 Capital Management
Puerto Rico
+$80.4K
3
MA
MYDA Advisors
New York
+$23.4K
4
BCM
BML Capital Management
Indiana
+$13.9K
5
US Bancorp
US Bancorp
Minnesota
+$13.7K

Top Sellers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
-$475K
2
Bank of America
Bank of America
North Carolina
-$274K
3
Barclays
Barclays
United Kingdom
-$262K
4
Renaissance Technologies
Renaissance Technologies
New York
-$163K
5
JP Morgan Chase
JP Morgan Chase
New York
-$42.6K

NGNE Hedge Fund Activity: Q1 2023 in Review

39 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Neurogene (NGNE) for Q1 2023, worth a combined $10.5M — up 22% from $8.66M a quarter earlier.

Sellers outnumbered buyers: 10 funds closed out of NGNE and 5 opened new positions — a net loss of 5 holders — while 15 trimmed existing stakes and 4 added.

The largest buyer was Morgan Stanley, adding an estimated $152K. The largest seller was Millennium Management, cutting an estimated $475K.

  • 39 institutional investors held Neurogene (NGNE) as of Q1 2023, down from 44 in Q4 2022.
  • Funds reported $10.5M of Neurogene stock for Q1 2023, up 22% quarter-over-quarter.
  • 5 funds opened new Neurogene positions in Q1 2023 and 10 closed out, a net change of -5 holders.
  • The largest Neurogene buyer in Q1 2023 was Morgan Stanley, an estimated $152K added.
  • The largest Neurogene seller in Q1 2023 was Millennium Management, an estimated $475K sold.

Based on aggregated 13F filings for Q1 2023.